| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785763 | Cancer Treatment Reviews | 2018 | 36 Pages |
Abstract
Genetic polymorphisms in pharmacokinetic and pharmacodynamic genes appear to influence aromatase inhibitor disposition, response and/or toxicity; however, prospective interventional studies are needed to understand the application of genomics to personalize aromatase inhibitor therapy in breast cancer patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Issam S. Hamadeh, Jai N. Patel, Stephanie Rusin, Antoinette R. Tan,